JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB216469

Carfilzomib, proteasome inhibitor

Be the first to review this product! Submit a review

|

(4 Publications)

MW 719.9 Da, Purity >98%. Potent, irreversible proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with carfilzomib results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis. Effective against multiple myeloma. Active in vivo.
1 Images
Chemical Structure - Carfilzomib, proteasome inhibitor (AB216469)
  • Chemical Structure

Lab

Chemical Structure - Carfilzomib, proteasome inhibitor (AB216469)

2D chemical structure image of ab216469, Carfilzomib, proteasome inhibitor

Key facts

CAS number

868540-17-4

Purity

>98%

Form

Solid

form

Molecular weight

719.9 Da

Molecular formula

C<sub>4</sub><sub>0</sub>H<sub>5</sub><sub>7</sub>N<sub>5</sub>O<sub>7</sub>

PubChem

11556711

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in ethanol to 25 mM

Biochemical name

Carfilzomib

Biological description

Potent, irreversible proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with carfilzomib results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis. Effective against multiple myeloma. Active in vivo.

Canonical smiles

CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

Isomeric smiles

CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

InChi

InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

InChiKey

BLMPQMFVWMYDKT-NZTKNTHTSA-N

IUPAC Name

(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions

Product protocols

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 14:7908 PubMed38036533

2023

Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype.

Applications

Unspecified application

Species

Unspecified reactive species

Gang Xue,Jianing Xie,Matthias Hinterndorfer,Marko Cigler,Lara Dötsch,Hana Imrichova,Philipp Lampe,Xiufen Cheng,Soheila Rezaei Adariani,Georg E Winter,Herbert Waldmann

Cell 186:346-362.e17 PubMed36638793

2023

An E3 ligase network engages GCN1 to promote the degradation of translation factors on stalled ribosomes.

Applications

Unspecified application

Species

Unspecified reactive species

Keely Oltion,Jordan D Carelli,Tangpo Yang,Stephanie K See,Hao-Yuan Wang,Martin Kampmann,Jack Taunton

Nature chemical biology 17:711-717 PubMed34035522

2021

Acute pharmacological degradation of Helios destabilizes regulatory T cells.

Applications

Unspecified application

Species

Unspecified reactive species

Eric S Wang,Alyssa L Verano,Radosław P Nowak,J Christine Yuan,Katherine A Donovan,Nicholas A Eleuteri,Hong Yue,Kenneth H Ngo,Patrick H Lizotte,Prafulla C Gokhale,Nathanael S Gray,Eric S Fischer

Blood 110:3281-90 PubMed17591945

2007

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Applications

Unspecified application

Species

Unspecified reactive species

Deborah J Kuhn,Qing Chen,Peter M Voorhees,John S Strader,Kevin D Shenk,Congcong M Sun,Susan D Demo,Mark K Bennett,Fijs W B van Leeuwen,Asher A Chanan-Khan,Robert Z Orlowski
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com